FILBERT
Financiado
An innovative implantable device and management platform to prevent chronic flui...
An innovative implantable device and management platform to prevent chronic fluid congestion
Pathologic fluid overload is a main clinical complication of congestive heart failure (CHF). CHF is a severe chronic disease affecting ~28 M people worldwide. Around 8 M of CHF patients are resistant to oral medications and underg...
Pathologic fluid overload is a main clinical complication of congestive heart failure (CHF). CHF is a severe chronic disease affecting ~28 M people worldwide. Around 8 M of CHF patients are resistant to oral medications and undergo frequent hospitalizations to remove extra fluids with aggressive acute treatments, all carrying severe complications. None of these treatments can prevent fluid accumulation. The Israeli SME Paragate Medical has developed FILBERT, a unique implantable peritoneal ultrafiltration system for diuretic resistant CHF patients. It enables 24/7 monitoring and gentle draining of extra fluids in the urinary system, preventing their accumulation. A remote treatment management platform allows physicians to continuously control patients’ conditions and timely adjust therapy to prevent fluid accumulation. FILBERT shifts the paradigm of fluid congestion care from the hospital to the home, improving patients’ quality of life and saving billions to healthcare systems.
ver más
Duración del proyecto: 48 meses
Fecha Inicio: 2023-07-17
Fecha Fin: 2027-07-31
Fecha Fin: 2027-07-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-17
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
13M€
Líder del proyecto
PARAGATE MEDICAL LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5